PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cited by (1,080)

Items 301–400 of 1,080

1. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
   Bernhard Mlecnik, Gabriela Bindea, Amos Kirilovsky, Helen K. Angell, Anna C. Obenauf, Marie Tosolini, SE Church, Pauline Maby, Angela Vasaturo, Mihaela Angelova et al. · 2016 · Science Translational Medicine
2. Targeting T Cell Co-receptors for Cancer Therapy
   Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2016 · Immunity
3. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
   Fernanda Gabriela Herrera, Catherine Ronet, María Ochoa-de-Olza, David Barras, Isaac Crespo, Massimo Andreatta, Jesus Corria-Osorio, Aodrenn Spill, Fabrizio Benedetti, Raphael Genolet et al. · 2021 · Cancer Discovery
4. Neoantigen landscape dynamics during human melanoma–T cell interactions
   Els M.E. Verdegaal, Noel F.C.C. de Miranda, Marten Visser, Tom J. Harryvan, Marit M. van Buuren, Rikke Sick Andersen, Sine Reker Hadrup, Caroline E. van der Minne, Remko Schotte, Hergen Spits et al. · 2016 · Nature
5. Acquired resistance to immunotherapy and future challenges
   Nicholas P. Restifo, Mark John Smyth, Alexandra Snyder · 2016 · Nature reviews. Cancer
6. Activation of STING-dependent innate immune signaling by s-phase-specific DNA damage in breast cancer
   Parkes, Eileen E., Walker, Steven M., Taggart, Laura E., McCabe, Nuala, Knight, Laura A., Wilkinson, Richard, McCloskey, Karen D., Buckley, Niamh E., Savage, Kienan I., Salto-Tellez, Manuel et al. · 2017 · Journal of the National Cancer Institute
7. Reversing T-cell Dysfunction and Exhaustion in Cancer
   Zarour, Hassane M. · 2016 · Clinical Cancer Research
8. Microsatellite instability status determined by next‐generation sequencing and compared with PD ‐L1 and tumor mutational burden in 11,348 patients
   Ari M. Vanderwalde, David B. Spetzler, Nianqing Xiao, Zoran Gatalica, John Lindsay Marshall · 2018 · Cancer Medicine
9. Management of Salivary Gland Malignancy: ASCO Guideline
   Jessica Lyn Geiger, Nofisat Ismaila, Beth Michelle Beadle, Jimmy J. Caudell, Nicole Grace Chau, Daniel G. Deschler, Christine M. Glastonbury, Marnie Kaufman, Eric Lamarre, Harold Lau et al. · 2021 · Journal of Clinical Oncology
10. Diffuse Glioma Heterogeneity and Its Therapeutic Implications
    James Nicholson, Howard Alan Fine · 2021 · Cancer Discovery
11. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
    Shindo, Koji, Yu, Jun, Suenaga, Masaya, Fesharakizadeh, Shahriar, Cho, Christy, Macgregor-Das, Anne, Siddiqui, Abdulrehman, Witmer, P. Dane, Tamura, Koji, Song, Tae Jun et al. · 2017 · Journal of Clinical Oncology
12. ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer
    Jiang, Yuming, Zhang, Qi, Hu, Yanfeng, Li, Tuanjie, Yu, Jiang, Zhao, Liying, Ye, Gengtai, Deng, Haijun, Mou, Tingyu, Cai, Shirong et al. · 2018 · Annals of Surgery
13. Colorectal Cancer Immunotherapy: Options and Strategies
    Nor Adzimah Johdi, NUR FAZILAH SUKOR · 2020 · Frontiers in Immunology
14. ATM Mutations in Cancer: Therapeutic Implications
    Michael Phillip Choi, Thomas J. Kipps, Razelle Kurzrock · 2016 · Molecular Cancer Therapeutics
15. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
    Timothy D. Gilligan, Daniel Wei Lin, Rahul Raj Aggarwal, David D. Chism, Nicholas Glenn Cost, Ithaar Derweesh, Hamid Emamekhoo, Darren Richard Feldman, Daniel M. Geynisman, Steven L. Hancock et al. · 2019 · Journal of the National Comprehensive Cancer Network
16. Genomic correlates of response to immune checkpoint blockade
    Keenan, Tanya E., Burke, Kelly P., Van Allen, Eliezer M. · 2019 · Nature Medicine
17. Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer
    Yu Zhang, Vidhi Chandra, Erick Marcelo Riquelme, Prasanta Dutta, Pompeyo R. Quesada, Amanda I. Rakoski, Michelle Annabel Zoltan, Nivedita Arora, Seyda Baydogan, William T. Horne et al. · 2020 · The Journal of Experimental Medicine
18. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology
    Shmatko, Artem, Ghaffari Laleh, Narmin, Gerstung, Moritz, Kather, Jakob Nikolas · 2022 · Nature Cancer
19. PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash, Valilou, Saeed Farajzadeh, Shabgah, Arezoo Gowhari, Aslani, Saeed, Alimardani, Malihe, Pasdar, Alireza, Sahebkar, Amirhossein · 2019 · Journal of Cellular Physiology
20. The Landscape of Targeted Therapies in TNBC
    Elena Vagia, Devalingam Mahalingam, Massimo Cristofanilli · 2020 · Cancers
21. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
    Balachandran, Vinod P., Beatty, Gregory L., Dougan, Stephanie K. · 2019 · Gastroenterology
22. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
    Tran, Eric, Robbins, Paul F, Rosenberg, Steven A · 2017 · Nature Immunology
23. Glioblastoma targeted therapy: updated approaches from recent biological insights
    Mehdi Touat, Ahmed Idbaïh, Marc Sanson, Keith Lloyd Ligon · 2017 · Annals of Oncology
24. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Valero, Cristina, Lee, Mark, Hoen, Douglas, Weiss, Kate, Kelly, Daniel W., Adusumilli, Prasad S., Paik, Paul K., Plitas, George, Ladanyi, Marc, Postow, Michael A. et al. · 2021 · Nature Communications
25. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer
    Shanshan Jiang, Yile Xie, Xiuying Xiao, Zi‐Ran Kang, Xiaolin Lin, Lu Zhang, Chu-Shu Li, Yun Qian, Pingping Xu, Xiao-Xu Leng et al. · 2023 · Cell Host & Microbe
26. The high price of anticancer drugs: origins, implications, barriers, solutions
    Vinay K. Prasad, Kevin De Jesús, Sham Mailankody · 2017 · Nature Reviews Clinical Oncology
27. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer
    Jon D. Vogel, Seth I. Felder, Anuradha R. Bhama, Alexander T. Hawkins, Sean Joseph Langenfeld, Virginia Oliva Shaffer, Amy J. Thorsen, Martin R. Weiser, George J. Chang, Amy Lee Lightner et al. · 2021 · Diseases of the Colon & Rectum
28. Molecular pathological classification of colorectal cancer
    Mike F. Müller, Ashraf E.K. Ibrahim, Mark Johan Arends · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
29. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
    Sandra P. D’Angelo, Luca Melchiori, Melinda S. Merchant, Donna B. Bernstein, John W. Glod, Rosandra Natasha Kaplan, Stephan A. Grupp, William D. Tap, Karen Chagin, Gwendolyn K. Binder et al. · 2018 · Cancer Discovery
30. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
    Zijun Yidan Xu-Monette, Jianfeng Zhou, Ken H. Young · 2017 · Blood
31. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
    2015 · New England Journal of Medicine
32. Therapeutic strategies to target RAS-mutant cancers
    Ryan, Meagan B., Corcoran, Ryan B. · 2018 · Nature Reviews Clinical Oncology
33. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D. et al. · 2016 · European Journal of Cancer
34. Immunotherapy in colorectal cancer: current achievements and future perspective
    Ahui Fan, Boda Wang, Xin Wang, Yongzhan Nie, Daiming Fan, Xiaodi Zhao, Yuanyuan Lu · 2021 · International Journal of Biological Sciences
35. New insights into the role of EMT in tumor immune escape
    Terry, Stéphane, Savagner, Pierre, Ortiz‐Cuaran, Sandra, Mahjoubi, Linda, Saintigny, Pierre, Thiery, Jean‐Paul, Chouaib, Salem · 2017 · Molecular Oncology
36. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
    Patrick J. Danaher, Sarah E. Warren, Rongze Olivia. Lu, Josue A. Samayoa, Amy H. Sullivan, Irena Pekker, Brett Wallden, Francesco Maria Marincola, Alessandra Cesano · 2018 · Journal for ImmunoTherapy of Cancer
37. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
    Suzanne I.S. Mosely, John E. Prime, Richard C.A. Sainson, Jens‐Oliver Koopmann, Dennis Y.Q. Wang, Danielle M. Greenawalt, Miika J. Ahdesmaki, Rebecca Leyland, Stefanie Mullins, Luciano Pacelli et al. · 2016 · Cancer Immunology Research
38. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
    Van Karlyle Morris, Mohamed E. Salem, Halla Sayed Nimeiri, Syma Iqbal, Preet Paul Singh, Kristen Keon Ciombor, Blasé N. Polite, Dustin A. Deming, Emily W. Chan, James Lloyd Wade et al. · 2017 · The Lancet Oncology
39. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
    Ahmed M Malki, Rasha Abu-El-Ruz, Ishita Gupta, Asma Allouch, Semir Vranić, Ala‐Eddin Al Moustafa · 2020 · International Journal of Molecular Sciences
40. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
    Wantong Song, Limei Shen, Ying Wang, Qi Liu, Tyler J. Goodwin, Jingjing Li, Olekasandra Dorosheva, Tianzhou Liu, Rihe Liu, Leaf Huang · 2018 · Nature Communications
41. Systemic therapies for intrahepatic cholangiocarcinoma
    Robin Kate Kelley, John A. Bridgewater, Gregory James Gores, Andrew Xiuxuan Zhu · 2020 · Journal of Hepatology
42. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
    Wei Ding, Betsy R LaPlant, Timothy G. Call, Sameer Ashok Parikh, Jose Francisco Leis, Rong Lucy He, Tait D. Shanafelt, Sutapa Sinha, Jennifer G. Le‐Rademacher, Andrew L. Feldman et al. · 2017 · Blood
43. The implications of IDH mutations for cancer development and therapy
    Christopher J. Pirozzi, Hai Yan · 2021 · Nature Reviews Clinical Oncology
44. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Xiangjiao Meng, Zhaoqin Huang, Feifei Teng, Ligang Xing, Jinming Yu · 2015 · Cancer Treatment Reviews
45. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
    Tiffany R. Hodges, Martina Ott, Joanne Xiu, Zoran Gatalica, Jeffrey J. Swensen, Shouhao Zhou, Jason T. Huse, John de Groot, Shulin Li, Willem W. Overwijk et al. · 2017 · Neuro-Oncology
46. Organoid Models of Tumor Immunology
    Kanako Yuki, Ning Cheng, Michitaka Nakano, Calvin Jay Kuo · 2020 · Trends in Immunology
47. Paradigms on Immunotherapy Combinations with Chemotherapy
    Diego Salas‐Benito, José Luis Perez‐Gracia, Mariano Ponz‐Sarvisé, Maria Esperanza Rodriguez-Ruiz, Iván Martínez‐Forero, Eduardo Castañón Álvarez, José María López-Picazo, Miguel F. Sanmamed, Ignacio Melero · 2021 · Cancer Discovery
48. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
    Eric Xueyu Chen, Derek J. Jonker, Jonathan M. Loree, Hagen Fritz Kennecke, Scott R. Berry, Félix Couture, Chaudhary E. Ahmad, John R. Goffin, Petr Kavan, Mohammed Harb et al. · 2020 · JAMA Oncology
49. Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Theodore Scott Nowicki, Siwen Hu‐Lieskovan, Antoni Ribas · 2018 · The Cancer Journal
50. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
    Samuel Jacob Klempner, David A. Fabrizio, Shalmali Bane, Marcia L. Reinhart, Tim Peoples, Siraj Mahamed Ali, Ethan S. Sokol, Garrett Michael Frampton, Alexa Betzig Schrock, Rachel Anhorn et al. · 2019 · The Oncologist
51. Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
    Alain Patrick Algazi, Katy K. Tsai, Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Zeynep Eroglu, Josep Maria Piulats, Patrick Alexander Ott, Douglas Buckner Johnson, Jimmy J. Hwang, ADIL I. DAUD et al. · 2016 · Cancer
52. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
    İbrahim Halil Şahin, Mehmet Akce, Olatunji Boladale Alese, Walid Labib Shaib, Gregory B. Lesinski, Bassel F. El‐Rayes, Christina Sing-Ying Wu · 2019 · British Journal of Cancer
53. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
    Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders S Bjartell, Alberto Bossi, Alberto Briganti, Robert Glen Bristow, Kim N. Chi, Noel William Clarke et al. · 2020 · European Urology
54. DNA sequencing technologies: 2006–2016
    Elaine R. Mardis · 2017 · Nature Protocols
55. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
    Jonathan Trujillo, Randy F. Sweis, Riyue Bao, Jason J. Luke · 2018 · Cancer Immunology Research
56. Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study
    Yamashita, Rikiya, Long, Jin, Longacre, Teri, Peng, Lan, Berry, Gerald, Martin, Brock, Higgins, John, Rubin, Daniel L, Shen, Jeanne · 2021 · The Lancet Oncology
57. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
    Chris Nevala-Plagemann, Manuel M. Hidalgo, Ignacio Garrido‐Laguna · 2019 · Nature Reviews Clinical Oncology
58. TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
    de Mingo Pulido, Álvaro, Gardner, Alycia, Hiebler, Shandi, Soliman, Hatem, Rugo, Hope S., Krummel, Matthew F., Coussens, Lisa M., Ruffell, Brian · 2018 · Cancer Cell
59. The Integrated Genomic Landscape of Thymic Epithelial Tumors
    Milan Radovich, Curtis R. Pickering, Ina Felau, Gavin Ha, Hailei Zhang, Heejoon Jo, Katherine A. Hoadley, Pavana Anur, Jiexin Zhang, Michael D. McLellan et al. · 2018 · Cancer Cell
60. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
    Karthik S. Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Karen Danoff · 2018 · CHEST Journal
61. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
    Posch, Florian, Silina, Karina, Leibl, Sebastian, Mündlein, Axel, Moch, Holger, Siebenhüner, Alexander, Samaras, Panagiotis, Riedl, Jakob, Stotz, Michael, Szkandera, Joanna et al. · 2018 · OncoImmunology
62. Combination immunotherapy: a road map
    Patrick Alexander Ott, Frank Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton, Jedd D. Wolchok · 2017 · Journal for ImmunoTherapy of Cancer
63. Improving radiotherapy in cancer treatment: Promises and challenges
    Helen H.W. Chen, Macus Tien Kuo · 2017 · Oncotarget
64. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
    Yifan Wang, Weiye Deng, Nan Li, Shinya Neri, Amrish Sharma, Wen Jiang, Steven Hsesheng Lin · 2018 · Frontiers in Pharmacology
65. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia
    Alvin Wei Tian Ng, Song Ling Poon, Mi Ni Huang, Jing Quan Lim, Arnoud Boot, Willie Yu, Yuka Suzuki, Saranya Thangaraju, Cedric Chuan Young Ng, Patrick B. O. Tan et al. · 2017 · Science Translational Medicine
66. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
    Yelena Yuriy Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid Khaled Chatila, Jaclyn Frances Hechtman, Geoffrey Yuyat Ku, Jamie Cathleen Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier et al. · 2017 · Cancer Discovery
67. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
    Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim Marie Hirshfield, Sherri Damare, Katherine Lane, Levi O. Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman et al. · 2016 · Journal of Clinical Investigation
68. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer
    Jianxia Li, Cheng Wu, Huabin Hu, Ge Qin, Xueqian Wu, Fan Bai, Jianwei Zhang, Yue Cai, Yan Jiun Huang, Chao Wang et al. · 2023 · Cancer Cell
69. A panoply of errors: polymerase proofreading domain mutations in cancer
    Emily Rayner, Inge C. van Gool, Claire Palles, Stephen E. Kearsey, Tjalling Bosse, Ian P.M. Tomlinson, David N. Church · 2016 · Nature reviews. Cancer
70. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data
    Sumit Middha, Liying Zhang, Khédoudja Nafa, Gowtham Jayakumaran, Donna Wong, Hyunjae Ryan Kim, Justyna Sadowska, Michael F. Berger, Deborah F. DeLair, Jinru Shia et al. · 2017 · JCO Precision Oncology
71. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
    Zishuo I. Hu, Jinru Shia, Zsofia Kinga Stadler, Anna M. Varghese, Marinela Capanu, Erin E. Salo‐Mullen, Maeve Aine Lowery, Luis Alberto Diaz, Diana L. Mandelker, Kenneth H. Yu et al. · 2018 · Clinical Cancer Research
72. Mechanisms regulating T-cell infiltration and activity in solid tumors
    Lanitis, E., Dangaj, D., Irving, M., Coukos, G. · 2017 · Annals of Oncology
73. Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment
    Xianwen Ren, Lei Zhang, Yuanyuan Zhang, Ziyi Li, Nathan O. Siemers, Zemin Zhang · 2021 · Annual Review of Immunology
74. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
    Ana Oaknin, Anna V. Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Amanda Mathews, Jubilee Brown, Maria-Pilar Barretina-Ginesta, Víctor Moreno, Adriano Gravina, Cyril Abdeddaim et al. · 2020 · JAMA Oncology
75. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
    Ángela Lamarca, Jorge Barriuso, Mairead Geraldine McNamara, Juan W. Valle · 2020 · Journal of Hepatology
76. Prospects for gene-engineered T cell immunotherapy for solid cancers
    Christopher Austin Klebanoff, Steven A. Rosenberg, Nicholas P. Restifo · 2016 · Nature Medicine
77. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology
    Antonia R. Sepulveda, Stanley R. Hamilton, Carmen Joseph Allegra, Wayne W. Grody, Allison M. Cushman‐Vokoun, William K. Funkhouser, Scott Kopetz, Christopher Hanyoung Lieu, Noralane M. Lindor, Bruce D. Minsky et al. · 2017 · Journal of Clinical Oncology
78. Prevalence and mutational determinants of high tumor mutation burden in breast cancer
    Romualdo Barroso‐Sousa, Esha Jain, Ofir Cohen, D. Kim, Jorge E. Buendia-Buendia, Eric P. Winer, NU Lin, Sara M. Tolaney, Nikhil Wagle · 2020 · Annals of Oncology
79. The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
    Peng, Zhi, Cheng, Siyuan, Kou, Yan, Wang, Ziqi, Jin, Rong, Hu, Han, Zhang, Xiaotian, Gong, Ji-fang, Li, Jian, Lu, Ming et al. · 2020 · Cancer Immunology Research
80. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
    Zhao, Lin-Yong, Mei, Jia-Xin, Yu, Gang, Lei, Lei, Zhang, Wei-Han, Liu, Kai, Chen, Xiao-Long, Kołat, Damian, Yang, Kun, Hu, Jian-Kun · 2023 · Signal Transduction and Targeted Therapy
81. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
    Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen · 2022 · Nature Reviews Drug Discovery
82. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer
    Lin, Anqi, Zhang, Jian, Luo, Peng · 2020 · Frontiers in Immunology
83. Implications of the tumor immune microenvironment for staging and therapeutics
    Janis Marie Taube, Jérôme Galon, Lynette Marie Sholl, Scott J. Rodig, Tricia R. Cottrell, Nicolás A. Giraldo, Alexander Spyridon Baras, Sanjay S. Patel, Robert A. Anders, David L. Rimm et al. · 2017 · Modern Pathology
84. Mechanisms of Cancer Resistance to Immunotherapy
    Rilan Bai, Naifei Chen, Lingyu Li, Nawen Du, Ling Bai, Zheng Lv, Huimin Tian, Jiuwei Cui · 2020 · Frontiers in Oncology
85. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
    Michael D. Iglesia, Joel S. Parker, Katherine A. Hoadley, Jonathan Stuart Serody, Charles M. Perou, Benjamin Garrett Vincent · 2016 · JNCI Journal of the National Cancer Institute
86. Exploring immunotherapy in colorectal cancer
    Weng, Junyong, Li, Shanbao, Zhu, Zhonglin, Liu, Qi, Zhang, Ruoxin, Yang, Yufei, Li, Xinxiang · 2022 · Journal of Hematology & Oncology
87. 3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids
    Schnalzger, Theresa E, de Groot, Marnix HP, Zhang, Congcong, Mosa, Mohammed H, Michels, Birgitta E, Röder, Jasmin, Darvishi, Tahmineh, Wels, Winfried S, Farin, Henner F · 2019 · The EMBO Journal
88. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
    Matteo Palmeri, Janice M. Mehnert, Ann Willman Silk, Salma K. Jabbour, Shridar Ganesan, Pallvi Popli, Gregory Riedlinger, Ryan D. Stephenson, Alexandre Buckley de Meritens, Aliza Leiser et al. · 2021 · ESMO Open
89. Alternative tumour-specific antigens
    Christof C. Smith, Sara R. Selitsky, Shengjie Chai, Paul M. Armistead, Benjamin Garrett Vincent, Jonathan Stuart Serody · 2019 · Nature reviews. Cancer
90. Recent advances in triple negative breast cancer: the immunotherapy era
    Antonio Marra, Giulia Viale, Giuseppe Curigliano · 2019 · BMC Medicine
91. Practical guidance for mismatch repair-deficiency testing in endometrial cancer
    Ellen Stelloo, Anna Mai Jansen, Elisabeth M. Osse, Remi A. Nout, Carien L. Creutzberg, Dina Ruano, David N. Church, Hans M. Morreau, Vincent T.H.B.M. Smit, Tom van Wezel et al. · 2016 · Annals of Oncology
92. Tumour burden and efficacy of immune-checkpoint inhibitors
    Dall’Olio, Filippo G., Marabelle, Aurélien, Caramella, Caroline, Garcia, Camilo, Aldea, Mihaela, Chaput, Nathalie, Robert, Caroline, Besse, Benjamin · 2022 · Nature Reviews Clinical Oncology
93. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
    Allen W. Zhang, Andrew McPherson, Katy Milne, David R. Kroeger, Phineas T. Hamilton, Alex Miranda, Tyler Funnell, Nicole S. Gierc, Camila P. E. de Souza, Sonya Laan et al. · 2018 · Cell
94. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers
    Singhi, Aatur D., George, Ben, Greenbowe, Joel R., Chung, Jon, Suh, James, Maitra, Anirban, Klempner, Samuel J., Hendifar, Andrew, Milind, Javle M., Golan, Talia et al. · 2019 · Gastroenterology
95. Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
    Albrecht Neeße, Christian Alexander Bauer, Daniel Öhlund, Matthias Lauth, Malte Buchholz, Patrick Michl, David A. Tuveson, Thomas Mathias Gress · 2018 · Gut
96. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ikuo Konishi · 2016 · International Journal of Clinical Oncology
97. Prognostic and Predictive Biomarkers in Gliomas
    Paulina Śledzińska, Marek G. Bebyn, Jacek Furtak, Janusz Kowalewski, Marzena Anna Lewandowska · 2021 · International Journal of Molecular Sciences
98. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis
    Jatin Roper, Tuomas Tammela, Naniye Malli Cetinbas, Adam Akkad, Ali Roghanian, Steffen Rickelt, Mohammad Almeqdadi, Katherine Wu, Matthias A. Oberli, Francisco J. Sánchez Rivera et al. · 2017 · Nature Biotechnology
99. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
    Liisa Chang, Minna Chang, Hanna M. Chang, Fuju Chang · 2017 · Applied immunohistochemistry & molecular morphology
100. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
     Fabiana Perna, Samuel Berman, Rajesh Kumar Soni, Jorge Mansilla‐Soto, Justin Eyquem, Mohamad Hamieh, Ronald C. Hendrickson, Cameron Brennan, Michel Sadelain · 2017 · Cancer Cell